 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. NASDAQ: GNMK to Roche is fair to GenMark shareholders. Under the terms of the merger agreement, Roche will acquire all outstanding shares of GenMark common stock for 24.05 per share in cash. Halper Sadeh encourages GenMark shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at 212 7 